Maryland 2025 Regular Session

Maryland House Bill HB779 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
4	4	[Brackets] indicate matter deleted from existing law.
5	5	hb0779
6	6
7	7	HOUSE BILL 779
8	8	E5 5lr0001
9	9	CF 5lr0002
10	10	By: Chair, Judiciary Committee (By Request – Departmental – Public Safety and
11	11	Correctional Services)
12	12	Introduced and read first time: January 29, 2025
13	13	Assigned to: Judiciary
14	14
15	15	A BILL ENTITLED
16	16
17	17	AN ACT concerning 1
18	18
19	19	Correctional Services – Medication Review Committee – Administration of 2
20	20	Psychotropic Medication to an Incarcerated Individual 3
21	21
22	22	FOR the purpose of authorizing the establishment of a medication review committee within 4
23	23	the Department of Public Safety and Correctional Services that convenes to 5
24	24	determine whether to approve the administration of psychotropic medication to a 6
25	25	certain incarcerated individual under certain circumstances; providing that 7
26	26	psychotropic medication may not be administered to an incarcerated individual who 8
27	27	refuses the medication except under certain circumstances; providing for the 9
28	28	membership and operating procedures of a medication review comm ittee; 10
29	29	establishing certain rights of an incarcerated individual in connection with the 11
30	30	convening of a medication review committee; establishing procedures for a certain 12
31	31	administrative review of the decision of a medication review committee; requiring a 13
32	32	certain treating physician to document certain matters under certain circumstances; 14
33	33	and generally relating to medication review committees. 15
34	34
35	35	BY adding to 16
36	36	Article – Correctional Services 17
37	37	Section 9–618 18
38	38	Annotated Code of Maryland 19
39	39	(2017 Replacement Volume and 2024 Supplement) 20
40	40
41	41	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 21
42	42	That the Laws of Maryland read as follows: 22
43	43
44	44	Article – Correctional Services 23
45	45
46	46	9–618. 24
47	47	2 HOUSE BILL 779
48	48
49	49
50	50	(A) (1) IN THIS SECTION THE F OLLOWING WORDS HAVE THE MEANINGS 1
51	51	INDICATED. 2
52	52
53	53	(2) “CLINICAL SERVICES MANAGEMENT TEAM” MEANS A TEAM 3
54	54	CONSISTING OF THE DIRECTOR OF MENTAL HEALTH, THE DEPUTY DIRECTOR OF 4
55	55	MENTAL HEALTH, THE CHIEF MEDICAL OFFICER, THE DEPUTY CHIEF MEDICAL 5
56	56	OFFICER, AND THE DIRECTOR OF NURSING OF THE DEPARTMENT . 6
57	57
58	58	(3) “COMMITTEE” MEANS A MEDICATION R EVIEW COMMITTEE 7
59	59	ESTABLISHED IN ACCOR DANCE WITH THIS SECT ION THAT CONVENES TO DETERMINE 8
60	60	WHETHER TO APPROVE T HE ADMINISTRATION OF PSYCHOTROPIC MEDICAT ION ON 9
61	61	A NONEMERGENCY BASIS TO AN INCARCERATED I NDIVIDUAL WHO REFUSE S TO 10
62	62	ACCEPT PSYCHOTROPIC MEDICATI ON AS PRESCRIBED . 11
63	63
64	64	(4) “LAY ADVISOR ” MEANS AN INDIVIDUAL WITHIN THE 12
65	65	DEPARTMENT WHO IS KNO WLEDGEABLE ABOUT MEN TAL HEALTH PRACTICE AND 13
66	66	CAN ASSIST INCARCERA TED INDIVIDUALS WITH UNDERSTANDING THE PR OCESS 14
67	67	OUTLINED IN THIS SEC TION. 15
68	68
69	69	(5) “LICENSED MENTAL HEALT H INFIRMARY” MEANS A DESIGNATED 16
70	70	UNIT WITHIN A STATE CORRECTIONAL FA CILITY THAT IS LICEN SED BY THE 17
71	71	MARYLAND DEPARTMENT OF HEALTH AS A MENTAL HE ALTH INFIRMARY . 18
72	72
73	73	(B) THIS SECTION APPLIES ONLY TO STATE CORRECTIONAL FA CILITIES. 19
74	74
75	75	(C) PSYCHOTROPIC MEDICATION M AY NOT BE ADMINISTER ED TO AN 20
76	76	INCARCERATED INDIVID UAL WHO REFUSES THE MEDICATION, EXCEPT: 21
77	77
78	78	(1) IN AN EMERGENCY , ON THE ORDER OF A PR ACTITIONER WHEN 22
79	79	THE INCARCERATED IND IVIDUAL PRESENTS A D ANGER TO THE LIFE OR SAFETY OF 23
80	80	SELF OR OTHERS ; OR 24
81	81
82	82	(2) IN A NONEMERGENCY , IF THE TREATING PRAC TITIONER HAS 25
83	83	RECOMMENDED THE INVO LUNTARY ADMINISTRATI ON OF PSYCHOTROPIC 26
84	84	MEDICATION BECAUSE : 27
85	85
86	86	(I) THE INCARCERATED IND IVIDUAL IS SUFFERING FROM A 28
87	87	MENTAL DISORDER RESU LTING IN BEHAVIOR TH AT CREATES A LIKELIHOOD OF 29
88	88	SERIOUS HARM TO SELF OR OTHERS; 30
89	89
90	90	(II) THE INCARCERATED IND IVIDUAL HAS REFUSED TO GIVE 31
91	91	INFORMED CONSENT TO THE ADMINISTRATION O F PSYCHOTROPIC MEDIC ATION; 32
92	92	HOUSE BILL 779 3
93	93
94	94
95	95	(III) OTHER TREATMENT MODA LITIES, INCLUDING 1
96	96	ENCOURAGING VOLUNTAR Y MEDICATION COMPLIANCE , HAVE BEEN ATTEMPTED 2
97	97	AND DOCUMENTED IN TH E MEDICAL RECORD ; 3
98	98
99	99	(IV) THE USE OF PSYCHOTRO PIC MEDICATION IS CL INICALLY 4
100	100	INDICATED AS THE MOS T APPROPRIATE TREATM ENT FOR THE INCARCER ATED 5
101	101	INDIVIDUAL’S CONDITION ACCORDIN G TO CURRENT PRACTIC E FOR RESTOR ING OR 6
102	102	PREVENTING FURTHER D ETERIORATION OF THE INCARCERATED INDIVID UAL’S 7
103	103	MENTAL OR PHYSICAL H EALTH; AND 8
104	104
105	105	(V) A COMMITTEE HAS DETE RMINED, IN ACCORDANCE WITH 9
106	106	THE PROVISIONS OF TH IS SECTION, THAT PSYCHOTROPIC ME DICATION SHOULD BE 10
107	107	ADMINISTERED OVER TH E OBJECTION OF THE INCARCE RATED INDIVIDUAL . 11
108	108
109	109	(D) (1) A COMMITTEE SHALL CONS IST OF THE FOLLOWING INDIVIDUALS 12
110	110	APPOINTED BY THE DIRECTOR OF MENTAL HEALTH FOR THE DEPARTMENT OR THE 13
111	111	DIRECTOR’S DESIGNEE: 14
112	112
113	113	(I) THE CHIEF PSYCHIATRI ST FOR THE REGION WH ERE THE 15
114	114	LICENSED MENTAL HEALTH INFI RMARY IS LOCATED ; 16
115	115
116	116	(II) ANOTHER PSYCHIATRIST ; AND 17
117	117
118	118	(III) A MENTAL HEALTH PROF ESSIONAL WHO IS NOT A 18
119	119	PHYSICIAN. 19
120	120
121	121	(2) THE DIRECTOR OF MENTAL HEALTH OR THE DIRECTOR’S 20
122	122	DESIGNEE SHALL APPOI NT A CHAIR OF THE CO MMITTEE FROM AMONG I TS 21
123	123	MEMBERSHIP. 22
124	124
125	125	(3) AN INDIVIDUAL WHO IS DIRECTLY RESPONSIBLE FOR 23
126	126	IMPLEMENTING THE TRE ATMENT PLAN FOR THE INCARCERATED INDIVID UAL 24
127	127	UNDER REVIEW MAY NOT SERVE AS A MEMBER OF THE COMMITTEE . 25
128	128
129	129	(E) THE DIRECTOR OF MENTAL HEALTH OR THE DIRECTOR’S DESIGNEE 26
130	130	SHALL ASS IGN AN IMPARTIAL LAY ADVISOR TO ASSIST TH E INCARCERATED 27
131	131	INDIVIDUAL WITH THE PROCESS SET FORTH IN THIS SECTION. 28
132	132
133	133	(F) THE DIRECTOR OF MENTAL HEALTH OR THE DIRECTOR’S DESIGNEE 29
134	134	SHALL GIVE THE INCAR CERATED INDIVIDUAL A ND THE LAY ADVISOR W RITTEN 30
135	135	NOTICE AT LEAST 5 BUSINESS DAYS BEFORE CONVENING THE COMMIT TEE THAT 31
136	136	SHALL INCLUDE THE FO LLOWING INFORMATION : 32
137	137	4 HOUSE BILL 779
138	138
139	139
140	140	(1) THE DATE, TIME, AND LOCATION OF THE SCHEDULED COMMITTEE 1
141	141	MEETING; 2
142	142
143	143	(2) THE PURPOSE OF THE C OMMITTEE; AND 3
144	144
145	145	(3) A COMPLETE DESCRIPTI ON OF THE RIGHTS OF AN INCARCERATED 4
146	146	INDIVIDUAL UNDER SUB SECTION (G) OF THIS SECTION. 5
147	147
148	148	(G) IN CONNECTION WITH TH E CONVENING OF A COM MITTEE, AN 6
149	149	INCARCERATED INDIVID UAL HAS THE RIGHT TO : 7
150	150
151	151	(1) ATTEND THE COMMITTEE MEETING, EXCEPT FOR THE DISCU SSION 8
152	152	CONDUCTED TO ARRIVE AT A DECISION; 9
153	153
154	154	(2) PRESENT INFORMATION , INCLUDING WITNESSES ; 10
155	155
156	156	(3) ASK QUESTIONS OF ANY PERSON PRESENTING IN FORMATION TO 11
157	157	THE COMMITTEE ; 12
158	158
159	159	(4) REQUEST ASSISTANCE F ROM A LAY ADVISOR ; AND 13
160	160
161	161	(5) BE INFORMED OF : 14
162	162
163	163	(I) THE IDENTITY OF THE ASSIGNED LAY ADVISOR ; 15
164	164
165	165	(II) THE INCARCERATED IND IVIDUAL’S DIAGNOSIS; AND 16
166	166
167	167	(III) THE CLINICAL NEED FO R THE PSYCHOTROPIC M EDICATION, 17
168	168	INCLUDING POTENTIAL SIDE EFFECTS AND MAT ERIAL RISKS AND BENE FITS OF 18
169	169	TAKING OR REFUSING T HE MEDICATION . 19
170	170
171	171	(H) THE CHAIR OF A COMMIT TEE MAY: 20
172	172
173	173	(1) POSTPONE OR CONTINUE THE COMMITTEE FOR GO OD CAUSE, FOR 21
174	174	UP TO 7 DAYS; AND 22
175	175
176	176	(2) TAKE APPROPRIATE MEA SURES NECESSARY TO C ONDUCT THE 23
177	177	COMMITTEE IN AN ORDE RLY MANNER . 24
178	178
179	179	(I) (1) BEFORE A COMMITTEE ME ETS, THE TREATING PSYCHIA TRIC 25
180	180	PROVIDER SHALL PROVI DE A DETAILED REPORT OF T HE INCARCERATED 26
181	181	INDIVIDUAL’S MEDICAL RECORD TO INCLUDE: 27
182	182	HOUSE BILL 779 5
183	183
184	184
185	185	(I) THE BASIS FOR THE RE QUEST TO ADMINISTER 1
186	186	PSYCHOTROPIC MEDICAT IONS ON A NONEMERGEN CY BASIS; 2
187	187
188	188	(II) THE INCARCERATED IND IVIDUAL’S DIAGNOSIS, DISTURBED 3
189	189	BEHAVIORS OBSERVED , AND CURRENT MENTAL STA TUS; 4
190	190
191	191	(III) A DESCRIPTION OF DAI LY FUNCTIONING ; 5
192	192
193	193	(IV) RECOMMENDED PSYCHOTR OPIC MEDICATION ; 6
194	194
195	195	(V) METHODS USED TO ENCO URAGE VOLUNTARY MEDI CATION 7
196	196	ADHERENCE ; 8
197	197
198	198	(VI) VOLUNTARY AND INVOLU NTARY MEDICATION HIS TORY; 9
199	199	AND 10
200	200
201	201	(VII) A DESCRIPTION OF THE LES S INTRUSIVE TREATMEN T 11
202	202	ALTERNATIVES CONSIDE RED OR ATTEMPTED . 12
203	203
204	204	(2) THE REPORT SHALL BE D ISTRIBUTED TO THE CO MMITTEE 13
205	205	MEMBERS NOT LESS THA N 72 HOURS BEFORE THE COM MITTEE IS TO MEET . 14
206	206
207	207	(J) BEFORE DETERMINING WH ETHER TO APPROVE THE ADMINISTRATION 15
208	208	OF PSYCHOTROPIC MEDI CATION, THE COMMITTEE SHALL : 16
209	209
210	210	(1) REVIEW THE REPORT GE NERATED BY THE TREAT ING 17
211	211	PSYCHIATRIC PROVIDER UNDER SUBSECTION (I) OF THIS SECTION; AND 18
212	212
213	213	(2) MEET FOR THE PURPOSE OF RECEIVING INFORMA TION AND 19
214	214	CLINICALLY ASSESSING THE INCARCERATED INDIVIDUAL ’S NEED FOR MEDICATIO N 20
215	215	BY: 21
216	216
217	217	(I) CONSULTING WITH THE INCARCERATED INDIVID UAL 22
218	218	REGARDING THE REASON FOR REFUSING THE PSY CHOTROPIC MEDICATION 23
219	219	PRESCRIBED AND THE I NCARCERATED INDIVIDU AL’S WILLINGNESS TO ACC EPT 24
220	220	ALTERNATIVE TREATMEN T, INCLUDING OTHER MEDI CATION; 25
221	221
222	222	(II) CONSULTING WITH THE TREATING CLINICIANS WHO ARE 26
223	223	RESPONSIBLE FOR INIT IATING AND IMPLEMENT ING THE INCARCERATED 27
224	224	INDIVIDUAL’S TREATMENT PLAN ABO UT THE CURRENT TREAT MENT PLAN AND 28
225	225	ALTERNATIVE MODES OF TREATMENT , INCLUDING MEDICATIONS , THAT HAVE BEEN 29
226	226	CONSIDERED ; 30
227	227	6 HOUSE BILL 779
228	228
229	229
230	230	(III) RECEIVING INFORMATIO N PRESENTED BY THE 1
231	231	INCARCERATED INDIVID UAL AND OTHER INDIVI DUALS PARTICIPATING IN THE 2
232	232	COMMITTEE ; 3
233	233
234	234	(IV) PROVIDING THE INCARC ERATED INDIVIDUAL WI TH AN 4
235	235	OPPORTUNITY TO ASK Q UESTIONS OF AN YONE PRESENTING INFO RMATION TO THE 5
236	236	COMMITTEE ; AND 6
237	237
238	238	(V) REVIEWING THE CONSEQ UENCES OF REQUIRING THE 7
239	239	ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N AND THE CONSEQUENC ES OF 8
240	240	CONTINUED REFUSAL OF PSYCHOTROPIC MEDICAT ION. 9
241	241
242	242	(K) THE COMMITTEE MAY APP ROVE THE ADMINI STRATION OF 10
243	243	PSYCHOTROPIC MEDICAT ION AND MAY RECOMMEN D AND APPROVE ALTERN ATIVE 11
244	244	MEDICATIONS , IF THE COMMITTEE DET ERMINES THAT : 12
245	245
246	246	(1) THE MEDICATION IS PR ESCRIBED BY A PSYCHI ATRIC PROVIDER 13
247	247	FOR THE PURPOSE OF T REATING THE INCARCER ATED INDIVIDUAL ’S MENTAL 14
248	248	DISORDER; 15
249	249
250	250	(2) THE ADMINISTRATION O F PSYCHOTROPIC MEDIC ATION 16
251	251	REPRESENTS A REASONA BLE EXERCISE OF PROF ESSIONAL JUDGMENT ; AND 17
252	252
253	253	(3) WITHOUT THE MEDICATI ON, THE INCARCERATED IND IVIDUAL IS 18
254	254	AT SUBSTANTIAL RISK OF CONTINUED SELF –HARM AND DANGEROUS B EHAVIORS 19
255	255	RESULTING FROM THE INDIVI DUAL: 20
256	256
257	257	(I) REMAINING SERIOUSLY MENTALLY ILL WITH NO 21
258	258	SIGNIFICANT RELIEF O F THE PSYCHIATRIC SY MPTOMS THAT : 22
259	259
260	260	1. CAUSE THE INCARCERAT ED INDIVIDUAL TO BE A 23
261	261	DANGER TO SELF OR OT HERS WHILE IN THE LI CENSED MENTAL HEALTH INFIRMARY; 24
262	262	OR 25
263	263
264	264	2. WOULD CAUSE THE INCA RCERATED INDIVIDUAL TO 26
265	265	BE A CONTINUED DANGE R TO SELF AND OTHER INCARCERATED INDIVID UALS IF 27
266	266	DISCHARGED FROM THE LICENSED MENTAL HEAL TH INFIRMARY; OR 28
267	267
268	268	(II) RELAPSING INTO A CON DITION IN WHICH THE 29
269	269	INCARCERATED INDIVID UAL IS UNABLE TO PROVIDE FOR THE I NDIVIDUAL’S OWN 30
270	270	ESSENTIAL HUMAN NEED S OF HEALTH AND SAFE TY. 31
271	271	HOUSE BILL 779 7
272	272
273	273
274	274	(L) (1) A COMMITTEE SHALL BASE ITS DECISION ON ITS CLINICAL 1
275	275	ASSESSMENT OF THE IN FORMATION CONTAINED IN THE INCARCERATED 2
276	276	INDIVIDUAL’S RECORD AND INFORMA TION PRESENTED TO TH E COMMITTEE. 3
277	277
278	278	(2) A COMMITTEE SHALL MEET PRIVATELY TO RENDER A DECISION. 4
279	279
280	280	(M) (1) THE COMMITTEE SHALL D OCUMENT ITS CONSIDER ATION OF THE 5
281	281	ISSUES AND THE BASIS FOR ITS DECISION ON THE ADMINISTRATION O F 6
282	282	PSYCHOTROPIC MEDICAT ION. 7
283	283
284	284	(2) THE COMMITTEE SHALL PROVIDE A WRITTEN DE CISION ON THE 8
285	285	ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N, WHICH SHALL BE PROVI DED TO 9
286	286	THE INCARCERATED IND IVIDUAL, THE LAY ADVISOR , AND THE INCARCERATED 10
287	287	INDIVIDUAL’S TREATMENT TEAM FOR INCLUSION IN THE MED ICAL RECORD. 11
288	288
289	289	(3) IF A COMMITTE E APPROVES THE ADMIN ISTRATION OF 12
290	290	PSYCHOTROPIC MEDICAT ION, THE DECISION SHALL S PECIFY: 13
291	291
292	292	(I) THE PSYCHOTROPIC MED ICATION APPROVED AND THE 14
293	293	DOSAGE AND FREQUENCY RANGE; 15
294	294
295	295	(II) THE DURATION OF THE APPROVAL, NOT TO EXCEED THE 16
296	296	MAXIMUM TIME ALLOWED UNDER SUBSE CTION (P) OF THIS SECTION; AND 17
297	297
298	298	(III) THE REASON THAT ALTE RNATIVE TREATMENTS , INCLUDING 18
299	299	OTHER MEDICATION , WERE REJECTED BY THE COMMITTEE. 19
300	300
301	301	(4) IF A COMMITTEE APPROV ES THE ADMINISTRATIO N OF 20
302	302	PSYCHOTROPIC MEDICAT ION, THE DECISION SHALL C ONTAIN NOTICE OF THE RIGHT 21
303	303	TO REQUEST AN ADMINI STRATIVE REVIEW UNDE R SUBSECTION (O) OF THIS 22
304	304	SECTION. 23
305	305
306	306	(N) IF A COMMITTEE APPROV ES THE ADMINISTRATIO N OF PSYCHOTROPIC 24
307	307	MEDICATION, THE LAY ADVISOR PROM PTLY SHALL: 25
308	308
309	309	(1) INFORM THE INCARCERA TED INDIVIDUAL OF TH E RIGHT TO SEEK 26
310	310	ADMINISTRATIVE REVIE W OF THE DECISION UN DER SUBSECTION (O) OF THIS 27
311	311	SECTION; AND 28
312	312
313	313	(2) ADVISE THE INCARCERA TED INDIVIDUAL OF TH E PROVISION FOR 29
314	314	RENEWAL OF AN APPROV AL UNDER SUBSECTION (P) OF THIS SECTION. 30
315	315	8 HOUSE BILL 779
316	316
317	317
318	318	(O) (1) AN INCARCERATED INDIV IDUAL MAY REQUEST AN 1
319	319	ADMINISTRATIVE REVIE W BY THE CLINICAL SERVICES MANAGEMENT TEAM WITHIN 2
320	320	2 BUSINESS DAYS AFTER RECEIPT OF THE DECIS ION OF THE COMMITTEE . 3
321	321
322	322	(2) WITHIN 1 BUSINESS DAY AFTER R ECEIPT OF A REQUEST FOR AN 4
323	323	ADMINISTRATIVE REVIE W, THE LAY ADVISOR SHAL L FORWARD THE RE QUEST TO 5
324	324	THE CLINICAL SERVICES MANAGEMENT TEAM. 6
325	325
326	326	(3) (I) AN INITIAL COMMITTEE DECISION AUTHORIZING THE 7
327	327	ADMINISTRATION OF PS YCHOTROPIC MEDICATIO N SHALL BE STAYED FO R 2 8
328	328	BUSINESS DAYS. 9
329	329
330	330	(II) IF A REQUEST FOR ADMI NISTRATIVE REVIEW IS FILED 10
331	331	UNDER THIS SUBSECTION, THE STAY SHALL REMAI N IN EFFECT UNTIL TH E 11
332	332	ISSUANCE OF THE ADMI NISTRATIVE DECISION . 12
333	333
334	334	(4) THE CLINICAL SERVICES MANAGEMENT TEAM SHALL ISSUE A 13
335	335	DECISION WITHIN 7 CALENDAR DAYS AFTER THE DECISION BY THE COMMITTEE. 14
336	336
337	337	(5) THE TREATING CLINICAL TEAM SHALL IMPLEMENT IMME DIATELY 15
338	338	ON RECEIPT THE DECIS ION OF THE CLINICAL SERVICES MANAGEMENT TEAM. 16
339	339
340	340	(P) (1) ADMINISTRATION OF PSY CHOTROPIC MEDICATION IN 17
341	341	ACCORDANCE WITH THIS SECTION MAY NOT BE A PPROVED FOR LONGER T HAN 90 18
342	342	DAYS. 19
343	343
344	344	(2) (I) BEFORE EXPIRATION OF AN APPROVAL PERIOD U NDER 20
345	345	PARAGRAPH (1) OF THIS SUBSECTION , IF THE INCARCERATED INDIVIDUAL 21
346	346	CONTINUES TO REFUSE PSYCHOTROPIC MEDICAT ION, A COMMITTEE MAY BE 22
347	347	CONVENED TO DECIDE W HETHER RENEWAL IS WA RRANTED. 23
348	348
349	349	(II) IF A COMMITTEE APPROV ES THE RENEWAL OF TH E 24
350	350	ADMINISTRATION OF PSY CHOTROPIC MEDICATION , THE ADMINISTRATION O F 25
351	351	MEDICATION NEED NOT BE INTERRUPTED WHEN THE INCARCERATED IND IVIDUAL 26
352	352	REQUESTS ADMINISTRAT IVE REVIEW OF THE RE NEWAL. 27
353	353
354	354	(Q) WHEN PSYCHOTROPIC MED ICATION IS ORDERED I N ACCORDANCE WITH 28
355	355	THIS SECTION, NOT LESS FREQUENTLY THAN EVERY 15 DAYS, THE TREATING 29
356	356	PHYSICIAN SHALL DOCU MENT ANY KNOWN BENEF ITS OF TAKING THE ME DICATION 30
357	357	TO THE INCARCERATED INDIVIDUAL AND SIDE EFFECTS OF THE MEDIC ATION THAT 31
358	358	AFFECT THE INCARCERA TED INDIVIDUAL . 32
359	359
360	360	SECTION 2. AND BE IT FU RTHER ENACTED, That this Act shall take effect 33
361	361	October 1, 2025. 34